PE20141206A1 - Procesos para la elaboracion de depsipeptidos macrociclicos y nuevos intermediarios - Google Patents

Procesos para la elaboracion de depsipeptidos macrociclicos y nuevos intermediarios

Info

Publication number
PE20141206A1
PE20141206A1 PE2013002370A PE2013002370A PE20141206A1 PE 20141206 A1 PE20141206 A1 PE 20141206A1 PE 2013002370 A PE2013002370 A PE 2013002370A PE 2013002370 A PE2013002370 A PE 2013002370A PE 20141206 A1 PE20141206 A1 PE 20141206A1
Authority
PE
Peru
Prior art keywords
alkanoyl
amino acid
macrociclic
depsipeptides
elaboration
Prior art date
Application number
PE2013002370A
Other languages
English (en)
Inventor
Murat Acemoglu
Heribert Hellstern
Felix Kollmer
John Lopez
Robert Schreiber
Christian Sprecher
Hans Stettler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46317455&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20141206(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20141206A1 publication Critical patent/PE20141206A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K11/00Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K11/00Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Cookers (AREA)
  • Cereal-Derived Products (AREA)

Abstract

REFERIDO A UN METODO PARA LA PREPARACION DE UN COMPUESTO DE DEPSIPEPTIDO CICLICO DE FORMULA (I) DONDE: A1 ES UNA FRACCION BIVALENTE DE UN AMINOACIDO CON UN GRUPO CARBOXILO O CARBAMOILO TERMINAL, EN ESPECIAL ASPARAGINA O GLUTAMINA, Y SE ENLAZA EN EL LADO DERECHO DE LA FORMULA (I) POR MEDIO DE UN CARBONILO CON EL RESTO DE LA MOLECULA; O ES ALCANOILO C1-8 O HIDROXI-ALCANOILO C1-8 FOSFORILADO; X ES ACILO Y SE ENLAZA POR MEDIO DE UN N DE A1; O ESTA AUSENTE SI A1 ES ALCANOILO C1-8 O HIDROXIALCANOILO C1-8 FOSFORILADO; R2 ES ALQUILO C1-8, EN ESPECIAL METILO; R3, R5, Y R7 SON CADA UNO LA CADENA LATERAL DE UN AMINOACIDO; R6 ES LA CADENA LATERAL DE UN HIDROXI-AMINOACIDO, EN ESPECIAL DE TIROSINA; Y ES H O ALQUILO C1-8; O UNA SAL DEL MISMO
PE2013002370A 2011-04-20 2012-04-19 Procesos para la elaboracion de depsipeptidos macrociclicos y nuevos intermediarios PE20141206A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161477319P 2011-04-20 2011-04-20

Publications (1)

Publication Number Publication Date
PE20141206A1 true PE20141206A1 (es) 2014-09-28

Family

ID=46317455

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013002370A PE20141206A1 (es) 2011-04-20 2012-04-19 Procesos para la elaboracion de depsipeptidos macrociclicos y nuevos intermediarios

Country Status (21)

Country Link
US (2) US8614289B2 (es)
EP (1) EP2699585A1 (es)
JP (2) JP5951006B2 (es)
KR (1) KR101580729B1 (es)
CN (2) CN103476789B (es)
AR (1) AR086168A1 (es)
AU (1) AU2012245980B2 (es)
BR (1) BR112013026660A2 (es)
CA (1) CA2833109A1 (es)
CL (2) CL2013003037A1 (es)
CO (1) CO6801799A2 (es)
EA (2) EA025546B1 (es)
GT (1) GT201300256A (es)
IL (1) IL228727A0 (es)
MA (1) MA35034B1 (es)
MX (1) MX337526B (es)
PE (1) PE20141206A1 (es)
SG (1) SG193918A1 (es)
TN (1) TN2013000385A1 (es)
TW (1) TW201249863A (es)
WO (1) WO2012143888A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101227231B1 (ko) 2007-08-17 2013-01-28 노파르티스 아게 시클릭 뎁시펩티드
US8680054B2 (en) 2011-04-20 2014-03-25 Novartis Ag Suspension type topical formulations comprising cyclic depsipeptide
AR086168A1 (es) 2011-04-20 2013-11-27 Novartis Ag Procesos para la elaboracion de depsipeptidos macrociclicos e intermediarios
US8987413B2 (en) 2012-10-09 2015-03-24 Novartis Ag Aldehyde acetal based processes for the manufacture of macrocyclic depsipeptides and new intermediates
US9067978B2 (en) * 2012-10-09 2015-06-30 Novartis Ag Solution phase processes for the manufacture of macrocyclic depsipeptides and new intermediates
US20170022254A1 (en) 2014-04-08 2017-01-26 Novartis Ag Novel Aldehyde Acetal Based Processes for the Manufacture of Macrocyclic Depsipeptides and New Intermediates
RU2707298C2 (ru) * 2015-05-20 2019-11-26 Мериал, Инк. Противогельминтные депсипептидные соединения
WO2017049128A1 (en) 2015-09-17 2017-03-23 Massachusetts Institute Of Technology Methods and systems for solid phase peptide synthesis
KR102031186B1 (ko) 2017-01-11 2019-11-08 주식회사 엘지생활건강 단백질 강도 강화용 조성물
WO2020018888A1 (en) 2018-07-20 2020-01-23 The Board Of Regents Of The University Of Oklahoma Antimicrobial peptides and methods of use

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3043252C2 (de) 1980-11-15 1982-12-02 Degussa Ag, 6000 Frankfurt Cyclische Acetale von N-Acylglutaminsäure -γ- semialdehyden, Verfahren zu deren Herstellung und ihre Verwendung
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
DE4421113A1 (de) 1994-06-16 1995-12-21 Biotechnolog Forschung Gmbh Chondramide, Gewinnungsverfahren, Mittel mit Chondramiden und Mischkultur zur Chondramid-Gewinnung
DE19828043A1 (de) 1998-06-24 1999-12-30 Bayer Ag Ektoparasitizide Mittel
JP2000154198A (ja) 1998-11-20 2000-06-06 Nisshin Flour Milling Co Ltd 環状デプシペプチドの固相合成方法及びその中間体
GB0108234D0 (en) * 2001-04-02 2001-05-23 Pharma Mar Sa Process for producing trunkamide A compounds
US20040110228A1 (en) 2002-04-01 2004-06-10 Mcalpine Shelli R. Combinatorial organic synthesis of unique biologically active compounds
JP5044214B2 (ja) 2003-06-06 2012-10-10 アレクシス・アクチボラゲット 皮膚状態または癌の処置のためのscce阻害剤としての縮合複素環化合物の使用
GB0322140D0 (en) 2003-09-22 2003-10-22 Pfizer Ltd Combinations
WO2005075667A1 (en) 2004-02-03 2005-08-18 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with kallikrein 7 (klk7)
EP1994181A4 (en) 2006-02-27 2010-05-19 Univ Arizona IDENTIFICATION AND USE OF NOVOPEPTIDES FOR THE TREATMENT OF CANCER
GB0715750D0 (en) 2007-08-13 2007-09-19 Karus Therapeutics Ltd Chemical compounds
KR101227231B1 (ko) * 2007-08-17 2013-01-28 노파르티스 아게 시클릭 뎁시펩티드
WO2009024528A1 (en) 2007-08-17 2009-02-26 Novartis Ag Use of cyclic depsipeptides to inhibit kallikrein 7
DE102007052391A1 (de) 2007-10-31 2009-05-07 Henkel Ag & Co. Kgaa Mattwachs
US20110112121A1 (en) 2009-07-06 2011-05-12 Joerg Berghausen Pharmaceutical Compositions and Solid Forms
US20120064013A1 (en) 2010-02-03 2012-03-15 David Marcos Foamable topical composition
KR101004362B1 (ko) 2010-03-19 2010-12-28 가톨릭대학교 산학협력단 자가 면역 질환 예방 및 치료용 TNF-α와 TWEAK 이중 길항제
US20120064136A1 (en) 2010-09-10 2012-03-15 Nanobio Corporation Anti-aging and wrinkle treatment methods using nanoemulsion compositions
CN109464393A (zh) 2011-01-24 2019-03-15 安特里奥公司 纳米颗粒组合物
JP5943258B2 (ja) 2011-01-24 2016-07-05 アンテリオス, インコーポレイテッド ナノ粒子組成物、その製剤およびその使用
AR086168A1 (es) 2011-04-20 2013-11-27 Novartis Ag Procesos para la elaboracion de depsipeptidos macrociclicos e intermediarios
US8680054B2 (en) 2011-04-20 2014-03-25 Novartis Ag Suspension type topical formulations comprising cyclic depsipeptide
US9067978B2 (en) 2012-10-09 2015-06-30 Novartis Ag Solution phase processes for the manufacture of macrocyclic depsipeptides and new intermediates
US8987413B2 (en) 2012-10-09 2015-03-24 Novartis Ag Aldehyde acetal based processes for the manufacture of macrocyclic depsipeptides and new intermediates
US20170022254A1 (en) 2014-04-08 2017-01-26 Novartis Ag Novel Aldehyde Acetal Based Processes for the Manufacture of Macrocyclic Depsipeptides and New Intermediates

Also Published As

Publication number Publication date
CL2013003037A1 (es) 2014-10-03
US20120277406A1 (en) 2012-11-01
SG193918A1 (en) 2013-11-29
AU2012245980B2 (en) 2015-01-29
KR101580729B1 (ko) 2015-12-28
TN2013000385A1 (en) 2015-01-20
GT201300256A (es) 2015-02-19
AR086168A1 (es) 2013-11-27
MX337526B (es) 2016-03-09
IL228727A0 (en) 2013-12-31
EA025546B1 (ru) 2017-01-30
MA35034B1 (fr) 2014-04-03
AU2012245980A1 (en) 2013-10-03
US8614289B2 (en) 2013-12-24
JP2014511899A (ja) 2014-05-19
US20140080995A1 (en) 2014-03-20
CN103476789A (zh) 2013-12-25
MX2013012188A (es) 2013-11-04
CN103476789B (zh) 2016-11-09
CL2015000688A1 (es) 2015-06-05
CA2833109A1 (en) 2012-10-26
CN104804072A (zh) 2015-07-29
WO2012143888A1 (en) 2012-10-26
JP2016164158A (ja) 2016-09-08
US9278997B2 (en) 2016-03-08
EP2699585A1 (en) 2014-02-26
KR20130140204A (ko) 2013-12-23
EA201391554A1 (ru) 2014-11-28
JP5951006B2 (ja) 2016-07-13
TW201249863A (en) 2012-12-16
EA201500734A1 (ru) 2015-11-30
BR112013026660A2 (pt) 2016-09-06
CO6801799A2 (es) 2013-11-29

Similar Documents

Publication Publication Date Title
PE20141206A1 (es) Procesos para la elaboracion de depsipeptidos macrociclicos y nuevos intermediarios
EA201490815A1 (ru) Составы этанерцепта, стабилизированные с помощью аминокислот
EA201890899A1 (ru) Модуляторы фарнезоидного x-рецептора
BR112018067792A2 (pt) preparação contendo o anticorpo
EA201291226A1 (ru) Композиции с высокой концентрацией антител
EA201390929A1 (ru) Антитела к pcsk9 и способы их применения
EA201301209A1 (ru) Производные пирролотриазинона в качестве ингибиторов p13k
EA201600506A1 (ru) КРИСТАЛЛИЧЕСКИЙ КОМПЛЕКС 1-ЦИАНО-2-(4-ЦИКЛОПРОПИЛБЕНЗИЛ)-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)БЕНЗОЛА, СПОСОБЫ ЕГО ПОЛУЧЕНИЯ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ
EA201400735A1 (ru) Производные альфа-амино бороновой кислоты, селективные ингибиторы иммунопротеасомы
EA201300239A1 (ru) Антитела к fap и способы их применения
UY34343A (es) Proteinas de unión al antígeno cd27l
BR112014011351A2 (pt) inibidores de acc e usos dos mesmos
EA201490778A1 (ru) АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ПРИМЕНЕНИЯ
EA201490596A1 (ru) Новые производные дигидрохинолин-2-она
GEP20186866B (en) FORMULATION FOR ANTI-α4β7 ANTIBODY
EA201490474A1 (ru) Аминохиназолины в качестве ингибиторов киназ
EA201691216A1 (ru) Композиции линаклотида с замедленным высвобождением
EA201892509A1 (ru) Антитела к гемагглютинину и способы применения
EA201391274A1 (ru) Аминохинолины в качестве ингибиторов киназ
EA201391389A1 (ru) Кристаллы антител против склеростина и составы на их основе
EA201391489A1 (ru) Композиции со сниженной вязкостью
EA201390260A1 (ru) Композиция для ухода за волосами
EA201692548A1 (ru) Минеральные аминокислотные комплексы активных веществ
TR201904327T4 (tr) Dimetilbenzoik asit bileşikleri.
EA201590041A1 (ru) Твердая форма холиновой соли вемурафениба

Legal Events

Date Code Title Description
FA Abandonment or withdrawal